Parkinson disease: Laying the foundations for disease-modifying therapies in PD

Nature Reviews Neurology

Volumn 11, Issue 10, 2015, Pages 553-554

  Brundin, Patrik ^a   Wyse, Richard ^b  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b Cure Parkinson's Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CREATINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GPI 1485; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RASAGILINE; SELEGILINE; UBIDECARENONE; NEUROPROTECTIVE AGENT;

BLADDER CANCER; CANCER INCIDENCE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; HEALTH CARE COST; HUMAN; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; SHORT SURVEY; UNIFIED PARKINSON DISEASE RATING SCALE; FEMALE; MALE;

FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; THIAZOLIDINEDIONES;

EID: 84942987517     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.150     Document Type: Short Survey

References (10)

1. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795-803 (2015).
2. Carta, A. R. PPAR-γ: therapeutic prospects in Parkinson's disease. Curr. Drug Targets 14, 743-751 (2013).
3. Levin, D. et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58, 493-504 (2015).
4. Petit, G. H., Olsson, T. T. & Brundin, P. The future of cell therapies and brain repair: Parkinson's disease leads the way. Neuropathol. Appl. Neurobiol. 40, 60-70 (2014).
5. Berg, D. et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord. 29, 454-462 (2014).
6. Santiago, J. A. & Potashkin, J. A. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med. 19, 176-186 (2013).
7. Brauer, R. et al. Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Med. 12, e1001854 (2015).
8. Aviles-Olmos, I. et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-344 (2014).
9. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/show/NCT01971242 (2015).
10. Brundin, P. et al. Linked clinical trials-the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J. Parkinsons Dis. 3, 231-239 (2013).